Medical Policies
Please note the following changes will be implemented to the designated medical policies.
- Effective 02/09/2022, MetroPlusHealth is implementing MPS 339 (Urinary Biomarkers) and MPS 340 (Unspecified Polymerase Chain Reaction Testing). We will not cover urinary biomarkers (88120, 88121) as a screening tool for bladder malignancy. We will cover unspecified polymerase chain reaction testing (87798) up to 2 units per DOS prior to requiring additional information.
- Effective 6/3/2021, MetroPlusHealth revised medical policy UM-MP231 Allergy Testing. We will only cover allergy testing when it is performed by board certified or residency trained Allergists/Immunologists or Dermatologists.
MetroPlus Health Plan utilizes clinical review criteria based upon a review of currently available clinical information(including Change Healthcare InterQual guidelines, clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors).
MetroPlus Health Plan expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by MetroPlus Health Plan, as some programs exclude coverage for services or supplies that MetroPlus Health Plan considers medically necessary. If there is a discrepancy between our internal established guidelines and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members.
- UM-MP200 Abdominoplasty Panniculectomy
- UM-MP201 Automatic External Defibrillators
- UM-MP202 Bariatric Surgery
- UM-MP203 Blepharoplasty
- UM-MP206 Capsule Endoscopy Camera Pill
- UM-MP208 Gender Dysphoria Services
- UM-MP214 Varicose Vein Treatment
- UM-MP215 Video Electroencephalographic Monitoring (VEEG)
- UM-MP218 Urine Drug Testing
- UM-MP219 Kymriah
- UM-MP221 Continuous Glucose Monitoring
- UM-MP222 Topical Oxygen Therapy
- UM-MP224 Exchange Transfusion for Sickle Cell Disease
- UM-MP227 Cardiac Rehab
- UM-MP228 MRgFUS
- UM-MP229 Pasteurized Human Donor Milk
- UM-MP230 Yescarta
- UM-MP231 Allergy Testing
- UM-MP232 Insulin Pump
- UM-MP234 Perinatal Care
- UM-MP235 Botulinumtoxin Therapy
- UM-MP237 Electromyography and Nerve Conduction Study
- UM-MP238 Erectile Dysfunction Treatment
- UM-MP245 EM Reimbursement Policy
- UM-MP246 CardioMEMS
- UM-MP249 Chemical Peels and Dermabrasion
- UM-MP251 Folic Acid Testing
- UM-MP252 Thyroid Testing Policy
- UM-MP253 Vitamin D Testing
- UM-MP255 Amylase Testing
- UM-MP256 Helicobacter Pylori Testing
- UM-MP271 Infertility Services
- UM-MP324 HIV Resistance Testing
- UM-MP325 Outpatient Physical and Occupational Therapy
- UM-MP332 Cell-Free Fetal DNA Testing
- UM-MP333 Adaptive Behavior Treatment (ABT)
- UM-MP334 Abecma
- UM-MP335 Tecartus
- UM-MP337 High Tech Radiology Studies (CT-MRI-PET)
- UM-MP339 Urinary Biomarker
- UM-MP340 Unspecified Polymerase Chain Reaction Testing
- UM-MP341 Intradialytic Parental Nutrition
- UM-MP342 Outpatient Speech Therapy
- UM-MP343 Clinical Trial Coverage of Routine Care
- UM-MP345 Tecvayli (teclistamab-cqyv)
- UM-MP346 Carvykti (ciltacabtagene autoleucel)
- UM-MP347 Breyanzi (lisocabtagene maraleucel)
- UM-MP349 Lyfegenia
- UM-MP350 Zynteglo (betibeglogene autotemcel)
Provider Resources
Already A Provider?
Talk To Us About Any Questions or Concerns
Monday–Friday | 8 a.m.–6 p.m. (ET)